Deimmunization of monoclonal antibodies

Area of Science:

• Immunology
• Biotechnology
• Protein Engineering

Background:

• Immunogenicity, triggered by T-cell epitopes in therapeutic proteins, limits treatment efficacy.
• Helper T-cells recognize these epitopes, leading to antibody production and therapeutic neutralization.

Purpose of the Study:

• To detail a method for creating deimmunized antibodies for mammalian cell production.
• To address the challenge of immunogenicity in protein-based therapeutics.

Main Methods:

• Deimmunization technology combines immunological and molecular biology techniques.
• Identifies and removes T-cell epitopes from protein sequences.
• Introduces mutations to eliminate epitopes while preserving antibody binding affinity.

Main Results:

• Deimmunized antibodies are created using human constant regions.
• Gene expression in mammalian cells facilitates the production of these modified antibodies.
• The described method enables the creation of therapeutic proteins with reduced immunogenicity.

Conclusions:

• Deimmunization is a viable strategy to overcome therapeutic protein immunogenicity.
• This approach allows for the development of safer and more effective antibody therapies.
• The method facilitates the production of deimmunized antibodies in mammalian systems.